SB-200646

Research use only, not for human use.

SB-200646 is a selective and potent?antagonist of 5-HT2B/5-HT2C receptor.

SB-200646 is a selective and potent?antagonist of 5-HT2B/5-HT2C receptor.

SB-200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency.

SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons. Animal Model:Male albino Sprague-Dawley rats (200-225 g at the beginning of treatment and 300-350 g at the time of the experiment)Dosage:20 mg/kg Administration:Intravenous injection; daily; for 21 days Result:Significantly decreased the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.

——

Endocrinology/Hormones

5-HT Receptor

5-HT2B|5-HT2C

——

——

143797-63-1

266.3

C15H14N4O??

>98% (HPLC)

DMSO:53 mg/mL (199.02 mM)

Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12

——

(-20℃)

With Ice Pack

≥ 2 years